Sparsentan for treatment of immunoglobulin A nephropathy: Latest study results
7 Mins
In patients with immunoglobulin A nephropathy, use of the endothelin 1 Type A/Ang II subtype 1 receptor antagonist sparsentan can decrease proteinuria and preserve kidney function